This website is for Israeli Healthcare Professionals only.

PRODUODOPA is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.1

CLINICAL DATA

PRODUODOPA efficacy and safety data from the 12- and 52-week studies.2,3

SAFETY

Read safety information including adverse events for PRODUODOPA.

DOSING AND ADMINISTRATION

Learn about the dosing and administration of PRODUODOPA.

References

  1. PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) prescribing information.
  2. Soileau MJ, et al. Lancet Neurol. 2022;21:1099–1109.
  3. Aldred J, et al. Neurol Ther. 2023 Aug 26. doi: 10.1007/5. s40120-023-00533.

IL-PRODD-240009. Date of preparation: May 2024.

Abbvie care contact details:

Abbvie care call center

052-81130040